{"id":"fyb206","safety":{"commonSideEffects":[{"rate":null,"effect":"Conjunctival hemorrhage"},{"rate":null,"effect":"Eye pain"},{"rate":null,"effect":"Floaters"},{"rate":null,"effect":"Intraocular pressure elevation"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"FYB206 functions as a VEGF/PlGF trap by binding and sequestering these angiogenic factors, preventing their interaction with endothelial growth factor receptors. This mechanism reduces pathological neovascularization and vascular permeability in retinal diseases. As a biosimilar, it is designed to have equivalent efficacy and safety to the reference product aflibercept.","oneSentence":"FYB206 is a biosimilar of aflibercept (Eylea) that inhibits vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) to reduce abnormal blood vessel growth in the eye.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:13:34.858Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Neovascular (wet) age-related macular degeneration"},{"name":"Diabetic macular edema"},{"name":"Retinal vein occlusion"}]},"trialDetails":[{"nctId":"NCT06551064","phase":"PHASE1","title":"Assessment of PK Similarity of FYB206 in Comparison With Keytruda in Resected Stage II or III Melanoma Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Formycon AG","startDate":"2024-07-01","conditions":"Melanoma, Stage II, Melanoma Stage III","enrollment":96},{"nctId":"NCT06643117","phase":"PHASE3","title":"Similar Efficacy, Safety, and Immunogenicity of FYB206 in Comparison to Keytruda as add-on to Chemotherapy in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC)","status":"TERMINATED","sponsor":"Formycon AG","startDate":"2024-10-03","conditions":"Non Small Cell Lung Cancer, Non-Squamous Non-Small Cell Lung Cancer","enrollment":25}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"FYB206","genericName":"FYB206","companyName":"Formycon AG","companyId":"formycon-ag","modality":"Biologic","firstApprovalDate":"","aiSummary":"FYB206 is a biosimilar of aflibercept (Eylea) that inhibits vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) to reduce abnormal blood vessel growth in the eye. Used for Neovascular (wet) age-related macular degeneration, Diabetic macular edema, Retinal vein occlusion.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}